Synthetic Biologics Inc.

09/12/2022 | Press release | Distributed by Public on 09/12/2022 07:17

Poster entitled “A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination with Durvalumab (MEDI4736) in Subjects with Recurrent/ Metastatic[...]